22 BOSTON WHARF ROAD, BOSTON, MA
Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Annual General Meeting Results - Akari Therapeutics Shareholder Vote
Akari Therapeutics Enters into $10 Million Securities Purchase Agreement
Akari Therapeutics Enters $12 Million Securities Purchase Agreement
Announces ADS Ratio Change
Shareholder Approval at Special General Meeting on March 2, 2026
Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
Shareholder Vote Results from Akari Therapeutics Special Meeting
Q2
Q1
Notice of Late Filing for Quarterly Report
FY 2025
Q3
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities
Notice of Exempt Offering of Securities
RW
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Amended Registration Statement for Depositary Shares
Submission Upload
Correspondence